{
    "nct_id": "NCT05775159",
    "official_title": "A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)",
    "inclusion_criteria": "* Age â‰¥18 years at the time of signing the ICF.\n* Provision of a signed and dated written ICF.\n* Confirmed locally advanced or metastatic solid tumor specified in substudy based on histopathology.\n* Adequate organ and bone marrow function.\n* At least 1 measurable not previously irradiated lesion per RECIST 1.1\n* Life expectancy of at least 12 weeks at the time of screening.\n* Willing and able to provide an adequate tumor sample.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of allogeneic organ transplantation.\n* Active or prior documented autoimmune or inflammatory disorders.\n* Uncontrolled intercurrent illness.\n* History of another primary malignancy, leptomeningeal carcinomatosis, and active primary immunodeficiency.\n* Active infection, brain metastases or spinal cord compression.\n* Participants co-infected with HBV and hepatitis D virus (HDV).\n* Previous treatment in the present study.\n* For substudy 1, history of hepatic encephalopathy within 12 months prior to treatment allocation.",
    "miscellaneous_criteria": ""
}